Analyst Research Report Snapshot

Title:

OREXO - BUILDING THE ZUBSOLV FRANCHISE

Price:

$10.00

Provider:

Edison Investment Research

Date:

07 Jan 2014

Pages:

16

Type:

AcrobatPDF

Companies referenced:

ORX.ST 4151.T ACT.N AZN.L BDSI.OQ GALE.OQ IGX.V INSY.OQ MEDAa.ST RB.L

Available for Immediate Download
Summary:

Orexo’s investment case centres on the commercial success of Zubsolv, a sublingual tablet for the maintenance treatment of opioid dependence. The US launch in September, through Orexo’s own sales infrastructure, is so far proceeding to management expectations. Reimbursement clarity should increase Zubsolv’s potential (an improved position is expected in H114), while longer-term market development and R&D investment in label expansion/lifecycle management will help build a defensible franchise. The outcome of pricing reviews and new clinical data, available from 2014, could expand Zubsolv’s current label and take market share from the current market leader, Reckitt Benckiser’s Suboxone. We value Orexo at SEK6.7bn or SEK203/share ($1.03bn or $31/share).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.